- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Patellar Luxation in Hong Kong
Total 22 results
-
The University of Hong KongUnknownAML | FLT3-ITD MutationHong Kong
-
The University of Hong KongCompletedAML | FLT3-ITD MutationHong Kong
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
The University of Hong KongCompletedAML | FLT3-ITD MutationHong Kong
-
The University of Hong KongUnknownNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIBHong Kong
-
The University of Hong KongRecruitingRecurrent Glioblastoma | Recurrent Glioma | Poly ADP Ribose Polymerase (PARP) Inhibitor | PTEN Gene Inactivation | IDH MutationHong Kong
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
AmgenActive, not recruitingAdvanced/Metastatic Solid Tumors With KRAS p.G12C MutationTaiwan, Hong Kong
-
Chinese University of Hong KongActive, not recruitingEUS Guided Cyanoacrylate Injection | Endoscopic Variceal Band Ligation | Hepatocelular Carcinoma | Esophageal Variceal BleedingHong Kong
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
-
Symphogen A/SCompletedNSCLC | Non Small Cell Lung Cancer | Oncology | MET Gene Mutation | MET Gene AmplificationUnited States, Korea, Republic of, Denmark, Hong Kong, Taiwan, Spain
-
Cullinan Therapeutics Inc.RecruitingNon Small Cell Lung Cancer | EGFR Exon 20 MutationUnited States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
-
ETOP IBCSG Partners FoundationAstraZenecaActive, not recruitingNSCLC Stage IV | EGFR Gene MutationSingapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
Relay Therapeutics, Inc.Active, not recruitingCholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, AdultUnited States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
-
BayerRecruitingAdvanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 MutationHong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
-
Recursion Pharmaceuticals Inc.RecruitingSolid Tumor | APC Gene Mutation | AXIN1 Gene MutationUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedCystic Fibrosis, Homozygous for the F508del CFTR MutationUnited States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
Vertex Pharmaceuticals IncorporatedCompletedCystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR MutationUnited States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditionsUnited States